-

AntiCancer Inc. Establishes Subsidiary CoronaCure to Develop Its Novel Therapeutic for COVID-19

SAN DIEGO--(BUSINESS WIRE)--AntiCancer Inc. has announced that it has established a fully owned subsidiary company, CoronaCure LLC, in order to develop its novel therapeutic for COVID-19.

The therapeutic, methioninase, which degrades the amino acid methionine, can selectively starve the coronavirus SARS-CoV-2, which causes COVID-19, of this amino acid that the virus needs in high amounts in order to replicate. In addition, methioninase can starve the infected cells which are producing the coronavirus in the body, since these cells also have an elevated requirement for methionine. Perhaps most important, methioninase can reduce or eliminate the inflammation that results in cytokine storm that is the eventual lethal event of COVID-19.

Current drugs being developed and marketed for COVID-19 are repurposed drugs that were originally developed for dissimilar viruses or diseases not related to COVID-19; for example hydroxychloroquine, remdesivir and Avigan. None of these drugs target the complicated biology of the virus that causes COVID-19. Methioninase, in contrast, targets the specific biology of this virus and therefore has great potential as a therapeutic for COVID-19.

Qinghong Han, Principal Investigator for the development of methioninase for COVID-19, said, “AntiCancer is looking for partners for its CoronaCure subsidiary to quickly develop methioninase to make it available for COVID-19 patients throughout the world.”

“The FDA approval process should be quite straightforward since the drug is administered orally with no side effects,” said Dr. Han.

AntiCancer, founded in 1984, has world headquarters in San Diego, with subsidiaries in Beijing, Tokyo and Seoul. AntiCancer also develops novel cancer therapeutics; stem cells from the hair follicle for regenerative medicine for nerve and spinal injury; PDOX mouse models of cancer for individualized therapy and drug discovery; tumor-targeting bacteria; three-dimensional tumor culture for rapid identification of active drugs; and contract research using AntiCancer’s unique technologies.

Contacts

Qinghong Han, MD
all@anticancer.com

Industry:

AntiCancer Inc.

Release Versions
English

Contacts

Qinghong Han, MD
all@anticancer.com

More News From AntiCancer Inc.

AntiCancer Inc. Has Received a New Patent That Revolutionizes Individualized Mouse Models of Human Cancer Patients by Increasing the Patient-tumor Establishment Rate in Mice to Close to 100%

SAN DIEGO--(BUSINESS WIRE)--AntiCancer Inc. announced it has just received US Patent 11,871,731 that describes a method to increase the rate of establishment of patient tumors in mice to close to 100%. Previously the establishment rates were much lower, in many cases only 10-20% in laboratories around the world. “The new method allows, for the first time, large scale and commercial success of establishing mouse models for each cancer patient to individualize and optimize their cancer therapy, a...

AntiCancer’s PDOX Mouse Model Has Demonstrated High Clinical Concordance Which Will Enable Precise Individualized Chemotherapy of Cancer Patients

SAN DIEGO--(BUSINESS WIRE)--AntiCancer Inc. of San Diego has announced its PDOX mouse model of human cancer patients has demonstrated high concordance of chemotherapy in the mouse and patient. “This new result means AntiCancer has made the first steps for precise, individualized cancer chemotherapy,” said Qinghong Han, Senior Scientist at AntiCancer Inc. “The PDOX mouse model has the patient’s tumor implanted in the same organ in the mouse as it was in the patient enabling very accurate predict...

AntiCancer Inc. Scientists Discover the Fundamental Basis of the Malignancy of Cancer

SAN DIEGO--(BUSINESS WIRE)--In a new article appearing in the current issue of the Cell Press scientific journal iScience, AntiCancer Inc. of San Diego has demonstrated that the addiction of cancer to the common amino acid methionine is the basis of the malignancy of cancer. The new article demonstrates that the excess methionine needed by cancer cells for their addiction is used to pathologically modify proteins that control gene expression (called histones), by a process called hyper-methylat...
Back to Newsroom